Can I Take St. John's Wort with Enclomiphene Citrate?

What Is Enclomiphene Citrate and How Is It Metabolized?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, used off-label to treat male secondary hypogonadism by blocking hypothalamic estrogen receptors and driving up gonadotropin-releasing hormone (GnRH) pulse frequency. The result is a rise in LH and FSH, which then stimulates testicular testosterone production while preserving spermatogenesis. Typical doses range from 12.5 mg to 25 mg daily.

The CYP450 Pathway for Enclomiphene

Clomiphene isomers, including enclomiphene, undergo hepatic oxidation primarily through CYP3A4, with secondary contributions from CYP2C9 and CYP2D6 [1]. Metabolites are conjugated and excreted in bile. Because CYP3A4 handles a large share of enclomiphene's first-pass and systemic clearance, any drug or supplement that up-regulates this enzyme will shorten the compound's half-life and lower its steady-state plasma concentration.

Why the Isomer Distinction Matters

Enclomiphene has a substantially shorter half-life than its cis-isomer (zuclomiphene), which accumulates for weeks. Enclomiphene's half-life is roughly 10 hours, making it particularly sensitive to CYP induction. A 30-50% increase in clearance from CYP3A4 induction could theoretically reduce peak plasma levels by a clinically meaningful margin, even at standard doses [2].

Receptor Mechanism Summary

Enclomiphene binds estrogen receptor-alpha at the hypothalamus, preventing negative feedback. LH surges, testosterone rises, and serum estradiol stays lower than with exogenous testosterone therapy. The entire mechanism depends on the drug reaching the hypothalamus in sufficient concentration. If plasma levels drop due to accelerated metabolism, the receptor occupancy falls and the therapeutic signal weakens.

What Is St. John's Wort and Why Does It Affect Drug Metabolism?

St. John's Wort (Hypericum perforatum) is a flowering plant sold widely as an over-the-counter supplement for mild depression, anxiety, and sleep complaints. It is one of the most thoroughly documented herbal inducers of drug-metabolizing enzymes in the human body [3].

Hyperforin: The Key Culprit

The primary active constituent responsible for enzyme induction is hyperforin, a phloroglucinol derivative that activates the pregnane X receptor (PXR). Activated PXR enters the nucleus and up-regulates transcription of CYP3A4, CYP2C9, and the efflux transporter P-glycoprotein (P-gp) [4]. Hypericin, the other well-known SJW constituent, contributes minimally to induction; preparations standardized to low hyperforin content show less induction, but no commercial product is completely free of it.

Magnitude of CYP3A4 Induction

The FDA has formally flagged SJW as a potent CYP3A4 inducer. A 2000 letter from the FDA warned that SJW "can cause serious interactions with drugs including indinavir, cyclosporine, oral contraceptives, warfarin, digoxin, and antiretrovirals" by inducing CYP3A4 [5]. Pharmacokinetic studies with midazolam (a pure CYP3A4 probe substrate) show that 14 days of standard SJW (300 mg three times daily, standardized to 0.3% hypericin) reduces midazolam AUC by approximately 30-54% [6]. Oral bioavailability drops proportionally.

Onset and Offset Timelines

Induction of CYP3A4 by SJW begins within 3-7 days of daily dosing. Full induction is typically established by day 14. Equally important: enzyme induction does not vanish immediately when SJW is stopped. CYP3A4 returns to baseline over approximately 14 days after discontinuation [3]. This washout period is clinically relevant. If a patient stops SJW on the same day they start enclomiphene, residual induction may still reduce drug exposure during the first two weeks of therapy.

The Specific Interaction Between St. John's Wort and Enclomiphene Citrate

No randomized pharmacokinetic trial has been published that measures enclomiphene plasma levels with and without concurrent SJW in human subjects. That absence of direct data does not mean the interaction is theoretical. It means the risk is extrapolated from first principles and from SJW's well-characterized effect on other CYP3A4 substrates.

Pharmacokinetic Prediction

Enclomiphene's reliance on CYP3A4 places it in the same metabolic category as drugs such as alprazolam, nifedipine, and simvastatin, all of which show AUC reductions of 30-60% when co-administered with SJW [3]. A 30% reduction in enclomiphene AUC at a starting dose of 12.5 mg/day would effectively expose the hypothalamus to the equivalent of roughly 8-9 mg per day, potentially below the threshold needed to meaningfully suppress estrogenic feedback. At 25 mg/day, the arithmetic is more favorable, but the outcome depends on individual metabolizer status and hyperforin content of the specific SJW product being used.

No Pharmacodynamic Overlap

This interaction is purely pharmacokinetic. SJW does not bind estrogen receptors in any clinically significant way at supplement doses. It does not directly alter LH, FSH, or testosterone secretion. The concern is not that SJW opposes enclomiphene's receptor-level action. The concern is that SJW reduces how much enclomiphene reaches its site of action.

P-glycoprotein: A Secondary Route

P-gp, also induced by SJW via PXR, acts as an intestinal efflux pump and pumps substrates back into the gut lumen after absorption [4]. If enclomiphene is a P-gp substrate (a question that has not been formally tested in the literature at the time of publication), P-gp induction would reduce oral bioavailability on top of the CYP3A4-mediated increase in hepatic clearance. The net effect would be additive.

Interaction Severity Classification

Using the Natural Medicines interaction framework (rated on mechanism strength and clinical consequence), the SJW-enclomiphene combination scores as moderate-to-significant. "Moderate" here means the interaction may reduce efficacy without producing overt toxicity. The risk is undertreated hypogonadism, not acute harm. That distinction matters for counseling: patients may not feel an adverse event. They may simply fail to respond to enclomiphene, leading to unnecessary dose escalation or an incorrect label of "treatment failure."

Clinical Consequences of Undertreated Secondary Hypogonadism

Secondary hypogonadism, when inadequately treated, carries meaningful health consequences beyond low libido. A 2019 analysis published in the Journal of Clinical Endocrinology and Metabolism found that men with total testosterone below 300 ng/dL had significantly higher rates of metabolic syndrome, cardiovascular risk markers, and bone mineral density loss compared with eugonadal controls [7]. If SJW silently blunts enclomiphene efficacy, the patient may remain testosterone-deficient without knowing the supplement is the cause.

What Labs to Watch

If a patient is already taking SJW and starts enclomiphene (or vice versa), the following monitoring schedule is reasonable:

• Baseline: total testosterone, free testosterone, LH, FSH, estradiol, SHBG
• Week 4: repeat total testosterone and LH to assess gonadotropin response
• Week 8: full repeat panel if week-4 testosterone is <400 ng/dL on a standard dose
• If testosterone remains low despite adequate dosing: assess SJW use, compliance, and metabolizer status

A strong LH response (LH rising above the upper limit of normal, typically >8 IU/L) with a flat testosterone response suggests testicular dysfunction, not a drug interaction. A flat LH response despite adequate enclomiphene dosing should raise suspicion that plasma enclomiphene levels are insufficient, and SJW co-use is a top candidate explanation.

Other Medications Affected by the Same Interaction Pattern

Understanding the SJW-enclomiphene risk becomes clearer when placed alongside SJW's documented interactions with other CYP3A4-dependent drugs.

Documented CYP3A4 Drug Interactions with SJW

• Cyclosporine: SJW co-administration has caused acute transplant rejection by dropping cyclosporine blood levels 30-64% [8].
• Oral contraceptives (ethinyl estradiol/norethindrone): breakthrough bleeding and contraceptive failure have been reported [3].
• Antiretrovirals (indinavir): AUC reduced by 57% in one pharmacokinetic study [5].
• Warfarin: INR destabilization due to accelerated CYP2C9-mediated warfarin metabolism [3].

Enclomiphene's therapeutic window is less narrow than cyclosporine's, and the consequence of failure is not acute rejection. Still, the mechanism is identical and the enzyme overlap is well-established.

What to Do If You Are Already Taking Both

Patients who discover they have been taking SJW concurrently with enclomiphene should not abruptly stop either agent without consulting their prescriber.

Step-by-Step Clinical Guidance

1. Tell your prescriber about the SJW use at your next appointment, or contact the practice before then if labs have shown a poor testosterone response.
2. If the decision is to stop SJW, allow a 14-day washout before re-evaluating whether enclomiphene dosing needs adjustment.
3. Re-check total testosterone and LH at the end of the washout. Many patients will see an improvement without a dose increase.
4. Do not self-increase enclomiphene dose to compensate for suspected SJW interaction without medical guidance. Supraphysiologic enclomiphene dosing carries risks including mood changes, visual disturbances, and excessive estrogen receptor blockade in bone.
5. If SJW is being used for depression or anxiety, discuss evidence-based prescription alternatives with your provider. A 2008 Cochrane review found SJW superior to placebo and comparable to standard antidepressants for mild-to-moderate depression in 29 trials (N=5,489) [9], but prescription SSRIs or SNRIs do not induce CYP3A4 at therapeutic doses and therefore do not carry the same interaction risk.

Choosing Safer Supplements Alongside Enclomiphene Citrate

Not all supplements carry the same interaction risk. Several compounds commonly used for men's health and testosterone support have low CYP3A4 interaction potential.

Lower-Risk Options to Discuss with Your Provider

• Vitamin D3 (cholecalciferol): no meaningful CYP3A4 induction; widely recommended as adjunct in hypogonadal men with vitamin D deficiency [10].
• Zinc: no CYP3A4 interaction; plays a role in testosterone biosynthesis and LH receptor sensitivity.
• Ashwagandha (Withania somnifera): limited CYP induction data; some evidence for modest LH and testosterone support in a 2019 randomized trial (N=57) showing a 14.7% increase in testosterone vs. Placebo [11]. Discuss with your prescriber before combining.
• Magnesium glycinate: no CYP interaction; associated with improved free testosterone in athletes with marginal magnesium status.

The contrast with SJW is instructive. These compounds do not activate PXR and do not meaningfully up-regulate the enzymes that clear enclomiphene. That does not make them universally safe in all contexts, but the specific pharmacokinetic concern does not apply.

Prescriber and Patient Communication: A Practical Note

The American Association of Clinical Endocrinology (AACE) guidelines on male hypogonadism emphasize a thorough medication and supplement review at each visit [12]. "Herbal and dietary supplements should be specifically queried, as patients often do not volunteer this information and many have clinically significant drug interactions," according to the AACE 2023 clinical practice guidelines for hypogonadism.

Patients frequently assume that "natural" means non-interacting. St. John's Wort is the single most widely studied example of why that assumption is incorrect. The FDA's 2000 Public Health Advisory stated clearly: "The degree to which St. John's Wort induces cytochrome P450 enzymes is not definitely known at this time, but appears to be significant." More than two decades of subsequent pharmacokinetic research have confirmed that assessment [5].

At a practical level, every HealthRX intake form asks specifically about herbal supplement use. If you are prescribed enclomiphene citrate and currently take SJW, flag it during intake. A simple medication review prevents weeks of subtherapeutic dosing and avoids the frustration of an apparently failed treatment course.

Summary of Key Interaction Facts

| Parameter | Detail | |---|---| | Interaction type | Pharmacokinetic (CYP3A4 and P-gp induction) | | Active inducer | Hyperforin in St. John's Wort | | Enzyme primarily affected | CYP3A4 (also CYP2C9, P-gp) | | Predicted AUC reduction | 30-54% based on CYP3A4 probe studies | | Onset of induction | 3-7 days of daily SJW use | | Washout after stopping SJW | ~14 days | | Direct human trial available | No (interaction extrapolated from class data) | | Severity rating | Moderate-to-significant | | Recommendation | Avoid combination; use 14-day washout before assessing enclomiphene efficacy |